Reference entry

Retatrutide

Also listed as LY3437943

Read the scope, examine the source, and keep your own question alongside the evidence.

Status labels apply within the product, route, and use described below. Read the limitations alongside that scope.

Scoped product status: Investigational
Evidence label: Randomized evidence

Status as of 2026-10-27

Reference fields

Sources for these fields

Product and use: Investigational; no FDA-approved product.
Route context: Studied as a subcutaneous injection.
Mechanism: Activates GIP, GLP-1 and glucagon receptors.
Evidence: A randomized obesity trial was funded by Lilly.
Limitations: Trial averages do not predict an individual outcome.
Safety: The trial reported gastrointestinal adverse events.

From a report to your question

Separate how closely a result is estimated from why the difference would matter. Inspect the units and any stated uncertainty, then ask what the measured change means in the terms of your question. If a report calls a result important, identify the standard behind that judgment rather than borrowing the adjective. A precise estimate and a useful answer are questions to examine separately. You can record what was measured clearly while leaving open whether the size or kind of difference addresses the concern you brought to the report.

Questions to consider

What units and uncertainty belong to the estimate I am examining?
Which standard supports the report's judgment that a difference matters?
Does the measured difference address my question, beyond being described precisely?

Sources

These references support the fields as a group. Follow a source to check the original wording and its scope.

FDA GLP-1FDA · Checked 2026-10-27
JastreboffPubMed · Checked 2026-10-27

Continue reading

Reading topics: Metabolism. These organize the library and do not describe recommended uses.

Educational reference information. No clinician review is claimed. This entry does not provide personal medical advice.